Zume
Search results
Zymergen was an American biotechnology company based in Emeryville, California. The company applies genomics and machine learning to research and design chemical producing genetically modified organisms. It claimed that its manufacturing process was safer and cheaper than traditional manufacturing, but was unable to demonstrate this.
Oct 19, 2022 · Ginkgo Bioworks, a company that designs and builds biological systems, announces its completed acquisition of Zymergen, a company that develops automation and software solutions for biological engineering. The acquisition is expected to enhance Ginkgo's platform and expand its product concepts and partnerships.
Jul 25, 2022 · Zymergen, a synthetic biology company that shifted to drug discovery in January, has been acquired by Ginkgo Bioworks for $300 million. Ginkgo plans to integrate Zymergen's automation and software into its cell engineering platform, while evaluating strategic alternatives for its drug discovery business.
- James Waldron
Jul 25, 2022 · Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, marking the final act in Zymergen’s dramatic and brisk fall from grace.
- Derek Saul
Oct 13, 2021 · Zymergen raised $500 million when it went public in April, on top of more than $1 billion in venture funding. By August, its CEO was out and the synthetic biology company wouldn’t say when it ...
Zymergen | 31,475 followers on LinkedIn. Zymergen is now a part of Ginkgo Bioworks!
Jul 26, 2022 · Ginkgo Bioworks has signed a definitive agreement for the acquisition of biotechnology company Zymergen in an all-stock deal worth nearly $300m. According to the agreement, 5.25% of the pro forma merged business will be owned by the stockholders of Zymergen following the acquisition.
